Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4)

Menlo park, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta car t cell therapies for cancer, today announced it granted inducement awards on may 31, 2022 (the “grant date”) under adicet's 2022 inducement plan as a material inducement to employment to four individuals hired by adicet in may 2022. the employees received, in the aggregate, non-qualified stock options to purchase 100,800 shar
ACET Ratings Summary
ACET Quant Ranking